Skip to Content



View full screen / Print PDF » Download PDF ⇩

Nuromol 200mg/500mg tablets



Each tablet contains ibuprofen 200 mg and paracetamol 500 mg.
For a full list of excipients see section 6.1



Film-coated tablets
White to off-white, oval shaped, pearlescent tablets de-bossed with an identifying helix.




Therapeutic indications

For the temporary relief of mild to moderate pain associated with migraine, headache,
backache, period pain, dental pain, rheumatic and muscular pain, pain of non-serious arthritis,
cold and flu symptoms, sore throat and fever. This product is especially suitable for pain
which requires stronger analgesia than ibuprofen or paracetamol alone.


Posology and method of administration
For short term-use only.
Undesirable effects may be minimised by using the lowest effective dose for the shortest
duration necessary to control symptoms (see section 4.4).

The patient should consult a doctor if the symptoms persist or worsen or if the product is
required for more than 3 days.

Adults: One tablet to be taken up to three times per day with water. Leave at least six hours
between doses.
If the one tablet dose does not control symptoms, a maximum of two tablets may be taken up
to three times a day. Leave at least six hours between doses.

Do not take more than six tablets (3000mg Paracetamol, 1200mg Ibuprofen) in any 24 hours
To minimise side effects, it is recommended that patients take Nuromol with food.

Elderly: No special dosage modifications are required (see section 4.4).
The elderly are at increased risk of the serious consequences of adverse reactions. If an
NSAID is considered necessary, the lowest effective dose should be used for the shortest
possible duration. The patient should be monitored regularly for gastrointestinal bleeding
during NSAID therapy.
Not for use by children under 18 years.
Method of Administration
For oral administration



This product is contraindicated:

In patients with a known hypersensitivity to ibuprofen, paracetamol or any other
excipients in the product.
In concomitant use with other Paracetamol-containing products – increased risk of
serious adverse effects (see Section 4.5).
In patients with a history of hypersensitivity reactions (e.g. bronchospasm,
angioedema, asthma, rhinitis, or urticaria) associated with acetylsalicylic acid or other
non-steroidal anti-inflammatory drugs (NSAIDs).
In patients with Active, or a history of recurrent peptic ulcer/haemorrhage (two or
more distinct episodes of proven ulceration or bleeding).
In patients with a history of, or an existing gastrointestinal ulceration/perforation or
bleeding, including that associated with NSAIDs (see Section 4.4).
Patients with defects in coagulation.
In patients with severe hepatic failure, severe renal failure or severe heart failure
(NYHA Class IV) (see Section 4.4).
In concomitant use with other NSAID containing products, including cyclooxygenase-2 (COX-2) specific inhibitors and doses of acetylsalicylic acid above
75 mg daily – increased risk of adverse reactions (see Section 4.5).


During the last trimester of pregnancy due to risk of premature closure of the foetal
ductus arteriosus with possible pulmonary hypertension (see Section 4.6)

Special warnings and precautions for use

Do not exceed the recommended dose.
If symptoms persist consult your doctor.
Keep out of the sight and reach of children.

The hazards of paracetamol overdose are greater in patients with non-cirrhotic alcoholic liver
disease. Immediate medical advice should be sought in the event of an overdose, even if the
patient feels well, because of the risk of delayed, serious liver damage.
Undesirable effects may be minimised by using the lowest effective dose for the shortest
duration necessary to control symptoms (see Section 4.2, and gastrointestinal and
cardiovascular risks below) and by patients taking the dose with food (see Section 4.2).


The elderly have an increased frequency of adverse reactions to NSAIDs especially
gastrointestinal bleeding and perforation which may be fatal (see Section 4.2).

Caution is required in patients with certain conditions:

Respiratory disorders:
In patients suffering from, or with a history of, bronchial asthma or allergic disease
NSAIDs have been reported to precipitate bronchospasm.

SLE and mixed connective tissue disease:
In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease
disorders there may be an increased risk of aseptic meningitis (see Section 4.8).

Cardiovascular and cerebrovascular effects

Appropriate monitoring and medical advice are required for patients with a history of
hypertension and/or mild to moderate congestive heart failure as fluid retention,
hypertension and oedema have been reported in association with NSAID therapy.
Clinical studies suggest that use of ibuprofen, particularly at a high dose (2400 mg/day)
may be associated with a small increased risk of arterial thrombotic events (e.g.
myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low
dose ibuprofen (e.g. ≤1200mg/day) is associated with an increased risk of arterial
thrombotic events.

Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III),
established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular
disease should only be treated with ibuprofen after careful consideration and high doses
(2400 mg/day) should be avoided. Careful consideration should be exercised before
initiating long-term treatment for patients with risk factors for cardiovascular events (e.g.
hypertension, hyperlipidaemia, diabetes mellitus, smoking) particularly if high doses of
ibuprofen (2400 mg/day) are required.

Cardiovascular, renal and hepatic impairment:
The administration of NSAIDs may cause a dose dependent reduction in prostaglandin
formation and precipitate renal failure. Patients at greatest risk of this reaction are those
with impaired renal function, cardiac impairment, liver dysfunction, those taking diuretics
and the elderly. Renal function should be monitored in these patients (see Section 4.3).

Gastrointestinal effects:
NSAIDS should be given with care to patients with a history of gastrointestinal disease
(ulcerative colitis, Crohn’s disease) as these conditions may be exacerbated (see section

Gastrointestinal (GI) bleeding, ulceration and perforation, which can be fatal, has been
reported with all NSAIDs at any time during treatment, with or without warning
symptoms or a previous history of serious GI events.

The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses,
in patients with a history of ulcer, particularly if complicated with haemorrhage or
perforation (see Section 4.3) and in the elderly. These patients should commence
treatment on the lowest dose available. Combination therapy with protective agents (e.g.
misoprostol or proton pump inhibitors) should be considered for these patients, and also
for patients requiring concomitant low dose acetylsalicylic acid, or other drugs likely to
increase gastrointestinal risk (see below and 4.5).

Patients with a history of GI toxicity, particularly the elderly, should report any unusual
abdominal symptoms (especially GI bleeding) particularly in the initial stages of

Caution should be advised in patients receiving concomitant medications which could
increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants
such as warfarin selective serotonin-reuptake inhibitors or antiplatelet agents such as
acetylsalicylic acid (see Section 4.5).

When GI bleeding or ulceration occurs in patients receiving ibuprofen containing
products, the treatment should be withdrawn.


Dermatological effects:
Serious skin reactions, some of them fatal, including exfoliative dermatitis, StevensJohnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in
association with the use of NSAIDs (see Section 4.8). Patients appear to be at highest risk
of these reactions early in the course of therapy, the onset of the reaction occurring in the
majority of cases within the first month of treatment. Use of this product should be
discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of

Impaired female fertility:
There is limited evidence that drugs which inhibit cyclo-oxygenase/prostaglandin
synthesis may impair female fertility by an effect on ovulation and is not recommended in
women attempting to conceive. This is reversible on withdrawal of treatment. In women
who have difficulties conceiving or who are undergoing investigation of infertility,
withdrawal of the product should be considered.

Interaction with other medicinal products and other forms of interaction

This product (like any other paracetamol containing products) is contraindicated in
combination with other paracetamol containing products – increased risk of serious adverse
effects (see Section 4.3).

This product (like any other ibuprofen containing products and NSAIDs) is contraindicated
in combination with:

Acetylsalicylic acid: Concomitant administration of ibuprofen and acetylsalicylic acid
is not generally recommended because of the potential of increased adverse effects,

unless low-dose acetylsalicylic acid (not above 75 mg daily) has been advised by a
doctor (see Section 4.4).

Experimental data suggest that Ibuprofen may competitively inhibit the effect of low
dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly.
Although there are uncertainties regarding extrapolation of these data to the clinical
situation, the possibility that regular, long-term use of ibuprofen may reduce the
cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No
clinically relevant effect is considered to be likely for occasional ibuprofen use (see
section 5.1)
Other NSAIDs including cyclo-oxygenase-2 selective inhibitors as these may
increase the risk of adverse effects (see Section 4.3).

This product (like any other paracetamol containing products) should be used with caution in
combination with:

Cholestyramine: The speed of absorption of paracetamol is reduced by
cholestyramine. Therefore, cholestyramine should not be taken within one hour if
maximal analgesia is required.
Metoclopramide and Domperidone: The absorption of paracetamol is increased by
metoclopramide and domperidone. However, concurrent use need not be avoided.
Warfarin: The anticoagulant effect of warfarin and other coumarins may be enhanced
by prolonged regular use of paracetamol with increased risk of bleeding; occasional
doses have no significant effect.

This product (like any other ibuprofen containing products and NSAIDs) should be used
with caution in combination with:

Anticoagulants: NSAIDs may enhance the effects of anticoagulants, i.e. warfarin (see
section 4.4).
Antihypertensives (ACE inhibitors and Angiotensin II Antagonists) and diuretics:
NSAIDs may reduce the effects of these drugs. In some patients with compromised
renal function (e.g. dehydrated patients or elderly patients with compromised renal
function) the co-administration of an ACE inhibitor or Angiotensin II antagonist and
agents that inhibit cyclo-oxygenase may result in further deterioration of renal
function, including possible acute renal failure, which is usually reversible. These
interactions should be considered in patients taking a coxib concomitantly with ACE
inhibitors or angiotensin II antagonists. Therefore, the combination should be
administered with caution, especially in the elderly. Patients should be adequately
hydrated and consideration should be given to monitoring of renal function after
initiation of concomitant therapy, and periodically thereafter. Diuretics may increase
the risk of nephrotoxicity of NSAIDs.
Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): Increased risk
of gastrointestinal bleeding (see Section 4.4).
Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR and
increase plasma glycoside levels.
Ciclosporin: Increased risk of nephrotoxicity.


Corticosteroids: Increased risk of gastrointestinal ulceration or bleeding (see
Section 4.4).
Lithium: Decreased elimination of lithium.
Methotrexate: Decreased elimination of methotrexate.
Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone
administration as NSAIDs can reduce the effect of mifepristone.
Quinolone antibiotics: Animal data indicate that NSAIDs can increase the risk of
convulsions associated with quinolone antibiotics. Patients taking NSAIDs and
quinolones may have an increased risk of developing convulsions.
Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are given with
Zidovudine: Increased risk of haematological toxicity with NSAIDS are given with
zidovudine. There is evidence of an increased risk of haemarthroses and haematoma
in HIV (+) haemophiliacs receiving concurrent treatment with zidovudine and

Pregnancy and lactation

There is no experience of use of this product in humans during pregnancy.
Congenital abnormalities have been reported in association with NSAID administration in
man; however these are low in frequency and do not appear to follow any discernible pattern.
In view of the known affects of NSAIDs on the foetal cardiovascular system (risk of closure
of ductus arteriosus), use in the last trimester is contraindicated. The onset of labour may be
delayed and duration increased with an increased bleeding tendency in both mother and child
(see Section 4.3). NSAIDs should not be used during the first two trimesters of pregnancy or
labour unless the potential benefit to the patient outweighs the potential risk to the foetus.

Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol use
at the recommended dosage.
Therefore if possible, the use of this product should be avoided in the first six months of
pregnancy and contraindicated in the last three months of pregnancy (see Section 4.3).

Ibuprofen and its metabolites can pass in very small amounts (0.0008% of the maternal dose)
into the breast milk. No harmful effects to infants are known.
Paracetamol is excreted in breast milk but not in a clinically significant amount. Available
published data do not contraindicate breastfeeding.
Therefore it is not necessary to interrupt breastfeeding for short-term treatment with the
recommended dose of this product.
See Section 4.4 regarding female fertility.


Effects on ability to drive and use machines

Undesirable effects such as dizziness, drowsiness, fatigue and visual disturbances are possible
after taking NSAIDs. If affected patients should not drive or operate machinery.


Undesirable effects

Clinical trials with this product have not indicated any other undesirable effects other than
those for ibuprofen or paracetamol alone.
The following table lists adverse effects from pharmacovigilance data experienced by patients
taking ibuprofen alone or paracetamol alone in short-term and long-term use.
Adverse events which have been associated with Ibuprofen alone or Paracetamol alone are
given below, tabulated by system organ class and frequency. Frequencies are defined as: very
common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare
(≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the
available data). Within each frequency grouping, adverse events are presented in order of
decreasing seriousness.

System Organ Class


Adverse Event

Lymphatic Very rare
System Disorders

Haematopoietic disorders1

Immune System Disorders


Hypersensitivity with urticaria and pruritus2

Very rare

Severe hypersensitivity reactions. Symptoms
can include facial, tongue and throat
swelling, dyspnoea, tachycardia, hypotension
(anaphylaxis, angioedema or severe shock)2

Psychiatric Disorders

Very rare

Confusion, depression and hallucinations

Nervous System Disorders


Headache and dizziness

Very rare

Aseptic meningitis3, paraesthesia,
neuritis and somnolence

Very rare

Visual disturbance

Eye Disorders



Labyrinth Very rare

Tinnitus and vertigo

Cardiac Disorders

Very rare

Cardiac failure and oedema4

Vascular Disorders

Very rare


Respiratory and thoracic Very rare
and mediastinal disorders

Respiratory reactivity including: asthma,
exacerbation of asthma, bronchospasm and

Gastrointestinal Disorders


Abdominal pain, vomiting, diarrhoea, nausea,
dyspepsia and abdominal discomfort5


peptic ulcer, gastrointestinal perforation or
haematemesis ,
exacerbation of colitis and Crohn's disease7

Very rare

Abnormal liver function, hepatitis and

Hepatobiliary Disorders

Skin and Subcutaneous Common
Tissue Disorders


Various skin rashes2

Very rare

Bullous reactions including Stevens-Johnson
syndrome, erythema multiforme and toxic
epidermal necrolysis2.Exfoliative dermatoses,
purpura, photosensitivity

Urinary Very rare

Nephrotoxicity in various forms, including
interstitial nephritis, nephrotic syndrome, and
acute and chronic renal failure9

General Disorders


and Very rare


Fatigue and malaise

Alanine aminotransferase increased, gammaglutamyltransferase increased and liver
function tests abnormal with paracetamol.
Blood creatinine increased, blood urea


Aspartate aminotransferase increased, blood
alkaline phosphatase increased, blood
haemoglobin decreased and platelet count

Description of Selected Adverse Reactions

Examples include agranulocytosis, anaemia, aplastic anaemia, haemolytic anaemia
leucopenia, neutropenia, pancytopenia and thrombocytopenia.
First signs are fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe
exhaustion, unexplained bleeding and bruising and nose bleeding.


Hypersensitivity reactions have been reported. These may consist of (a) non-specific allergic
reactions and anaphylaxis, (b) respiratory tract activity, e.g. asthma, aggravated asthma,
bronchospasm or dyspnoea, or (c) various skin reactions, including rashes of various types,
pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatoses
(including toxic epidermal necrolysis, Stevens-Johnson Syndrome and erythema multiforme).


The pathogenic mechanism of drug-Induced aseptic meningitis is not fully understood.
However, the available data on NSAID-related aseptic meningitis points to a hypersensitivity
reaction (due to a temporal relationship with drug intake, and disappearance of symptoms
after drug discontinuation). Of note, Single cases of aseptic meningitis in patients with
existing autoimmune disorders (such as systemic lupus erythematosus and mixed connective
tissue disease) during treatment with Ibuprofen, with symptoms such as: stiff neck, headache,
nausea, vomiting, fever or disorientation have been observed (see Section 4.4).


Clinical studies suggest that use of ibuprofen particularly at high a dose (2400mg/day) may
be associated with a small increased risk of arterial thrombotic events (for example
myocardial infarction or stroke) (see section 4.4).


The adverse events observed most often are gastrointestinal in nature.


Sometimes fatal, particularly in the elderly.


See section 4.4.


In overdose Paracetamol can cause acute hepatic failure, hepatic failure, hepatic necrosis and
liver injury (see Section 4.9).


Especially in long-term use, associated with increased serum urea and oedema.
Also includes papillary necrosis.

Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the Yellow
Card Scheme at




Liver damage is possible in adults who have taken 10 g (equivalent to 20 tablets) or more of
paracetamol. Ingestion of 5 g (equivalent to 10 tablets) or more of paracetamol may lead to
liver damage if the patient has one or more of the risk factors below:


Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone,
rifampicin, St John's Wort or other drugs that induce liver enzymes.
Regularly consumes alcohol in excess of recommended amounts.
Is likely to be glutathione depleted e.g. eating disorders, cystic fibrosis, HIV
infection, starvation, cachexia


Symptoms of paracetamol overdose in the first 24 hours include pallor, nausea, vomiting,
anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after
ingestion as liver function tests become abnormal. Abnormalities of glucose metabolism and
metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to
encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal
failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and

proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and
pancreatitis have been reported.


Immediate treatment is essential in the management of paracetamol overdose. Despite a lack
of significant early symptoms, patients should be referred to hospital urgently for immediate
medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the
severity of overdose or the risk of organ damage. Management should be in accordance with
established treatment guidelines.
Treatment with activated charcoal should be considered if the overdose has been taken within
1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after
ingestion (earlier concentrations are unreliable).
Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol
however; the maximum protective effect is obtained up to 8 hours post ingestion. The
effectiveness of the antidote declines sharply after this time.
If required the patient should be given intravenous-N-acetylcysteine, in line with the
established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable
alternative for remote areas, outside hospital.
Patients who present with serious hepatic dysfunction beyond 24 hours from ingestion should
be managed in accordance with established guidelines.


In children ingestion of more than 400 mg/kg of Ibuprofen may cause symptoms. In adults the
dose response effect is less clear cut.
The half-life in overdose is 1.5-3 hours.


Most patients who have ingested clinically important amounts of NSAIDs will develop no
more than nausea, vomiting, epigastric pain, or more rarely diarrhoea. Tinnitus, headache and
gastrointestinal bleeding are also possible. In more serious poisoning, toxicity is seen in the
central nervous system, manifesting as drowsiness, occasionally excitation and disorientation
or coma. Occasionally patients develop convulsions. In serious poisoning metabolic acidosis
may occur and the prothrombin time / INR may be prolonged, probably due to interference
with the actions of circulating clotting factors. Acute renal failure and liver damage may
occur if there is a co-incident of dehydration. Exacerbation of asthma is possible in


Management should be symptomatic and supportive and include the maintenance of a clear
airway and monitoring of cardiac and vital signs until stable. Consider oral administration of
activated charcoal if the patient presents within 1 hour of ingestion of a potentially toxic
amount. If frequent or prolonged, convulsions should be treated with intravenous diazepam or
lorazepam. Give bronchodilators for asthma.




Pharmacodynamic properties

ATC Code: M01AE51 – Musculoskeletal system, anti-inflammatory and antirheumatic
products, non-steroids, propionic acid derivatives. Ibuprofen combinations.

The pharmacological actions of ibuprofen and paracetamol differ in their site and mode of
action. These complementary modes of action are synergistic which results in greater
antinociception and antipyresis than the single actives alone.
Ibuprofen is an NSAID that has demonstrated its efficacy in the common animal experimental
inflammation models by inhibition of prostaglandin synthesis. Prostaglandins sensitise
nociceptive afferent nerve terminals to mediators such as bradykinin. Ibuprofen therefore
elicits an analgesic effect through peripheral inhibition of the cycloxygenase-2 (COX-2)
isoenzyme with a subsequent reduction in sensitisation of nociceptive nerve terminals.
Ibuprofen has also been shown to inhibit induced-leucocyte migration into inflamed areas.
Ibuprofen has a pronounced action within the spinal cord due, in part, to the inhibition of
COX. Ibuprofen’s antipyretic effects are produced by the central inhibition of prostaglandins
in the hypothalamus. Ibuprofen reversibly inhibits platelet aggregation. In humans, ibuprofen
reduces inflammatory pain, swellings and fever.

Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose
acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Some
pharmacodynamic studies show that when single doses of ibuprofen 400mg was taken within
8 h before or within 30 min after immediate release acetylsalicylic acid dosing (81mg), a
decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet
aggregation occurred. Although there are uncertainties regarding extrapolation of these data

to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the
cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically
relevant effect is considered to be likely for occasional ibuprofen use (see section 4.5).

Paracetamol’s exact mechanism of action is still not completely defined; however there is
considerable evidence to support the hypothesis of a central antinociceptive effect. Various
biochemical studies point to inhibition of central COX-2 activity. Paracetamol may also
stimulate the activity of descending 5-hydroxytryptamine (serotonin) pathways that inhibit
nociceptive signal transmission in the spinal cord. Evidence has shown that paracetamol is a
very weak inhibitor of peripheral COX-1 and 2 isoenzymes.

The clinical efficacy of ibuprofen and paracetamol has been demonstrated in pain associated
with headache, toothache and dysmenorrhoea, and fever; furthermore efficacy has been
shown in patients with pain and fever associated with cold and influenza and in pain models
such as sore throat, muscular pain or soft tissue injury and backache.
This product is especially suitable for pain which requires stronger pain relief than ibuprofen
400 mg or paracetamol 1000 mg alone, and faster pain relief than ibuprofen.

Summary of 2 tablet clinical data

A randomised, double-blind placebo-controlled studies were conducted with the combination
using the acute pain model of post-operative dental pain. The studies show that:

This product provides more effective pain relief than paracetamol 1000 mg
(p<0.0001) and ibuprofen 400 mg (p< 0.05) which are clinically and statistically
This product has a fast onset of action with ‘confirmed perceptible pain relief’
achieved in a median of 18.3 minutes. The onset of action was significantly more
rapid than for ibuprofen 400 mg (23.8 minutes, p=0.0015). ‘Meaningful pain relief’
for this product was achieved in a median of 44.6 minutes, which was significantly
faster than for ibuprofen 400 mg (70.5 minutes, p<0.0001)..
Duration of analgesia was significantly longer for this product (9.1 hours) compared
to paracetamol 500 mg (4 hours) or 1000 mg (5 hours).
The global evaluation of the study medication by the subjects showed high levels of
satisfaction with 93.2% rating the product as ‘good’, ‘very good’ or ‘excellent’ in
achieving pain relief. The fixed combination product performed significantly better
than paracetamol 1000 mg (p<0.0001).

A randomised, double-blind controlled clinical study was conducted with the product in the
treatment of chronic knee pain. The study showed that:


The product provides more effective pain relief than paracetamol 1000 mg in shortterm treatment (p<0.01) and long term treatment (p<0.01).
The global evaluation of the product by the subjects showed high levels of
satisfaction with 60.2% rating the product as ‘good’ or ‘excellent’ as a long term
treatment for a painful knee. The product performed significantly better than
paracetamol 1000 mg (p<0.001).

Pharmacokinetic properties

Ibuprofen is well absorbed from the gastrointestinal tract and is extensively bound to plasma
proteins. Ibuprofen diffuses into the synovial fluid. Plasma levels of ibuprofen from this
product are detected from 5 minutes with peak plasma concentrations achieved within
1-2 hours after ingestion on an empty stomach. When this product was taken with food peak
ibuprofen plasma levels were lower and delayed by a median of 25 minutes, but overall extent
of absorption was equivalent.

Ibuprofen is metabolised in the liver to two major metabolites with primary excretion via the
kidneys, either as such or as major conjugates, together with a negligible amount of
unchanged ibuprofen. Excretion by the kidney is both rapid and complete. The elimination
half-life is approximately 2 hours.

In limited studies, ibuprofen appears in the breast milk in very low concentrations.

No significant differences in ibuprofen pharmacokinetic profile are observed in the elderly.

Paracetamol is readily absorbed from the gastrointestinal tract. Plasma protein binding is
negligible at usual therapeutic concentrations, although this is dose-dependent. Plasma levels
of paracetamol from this product are detected from 5 minutes with peak plasma
concentrations occurring at 0.5-0.67 hours after ingestion on an empty stomach. When this
product was taken with food peak paracetamol plasma levels were lower and delayed by a
median of 55 minutes, but overall extent of absorption was equivalent.

Paracetamol is metabolised in the liver and excreted in the urine mainly as the glucuronide
and sulphate conjugates, with about 10% as glutathione conjugates. Less than 5% is excreted
as unchanged paracetamol. The elimination half-life is approximately 3 hours.

A minor hydroxylated metabolite, which is usually produced in very small amounts by mixed
function oxidases in the liver and detoxified by conjugation with liver glutathione, may
accumulate following paracetamol overdose and cause liver damage.

No significant differences in the paracetamol pharmacokinetic profile are observed in the

The bioavailability and pharmacokinetic profiles of ibuprofen and paracetamol taken as this
product are not altered when taken in combination as a single or repeat dose.

This product is formulated using a technology which releases both Ibuprofen and Paracetamol
simultaneously, so that the active ingredients deliver a combination effect.


Preclinical safety data

The toxicological safety profile of ibuprofen and paracetamol has been established in animal
experiments and in humans from extensive clinical experience. There are no new preclinical
data of relevance to the prescriber which are additional to the data already presented in this
Summary of Product Characteristics.




List of excipients

Croscarmellose sodium
Microcrystalline cellulose
Colloidal anhydrous silica
Magnesium stearate
Stearic acid

Film Coat
Polyvinyl alcohol
Titanium Dioxide

Potassium aluminium silicate (E555)



Not applicable


Shelf life

3 years.


Special precautions for storage

This medicinal product does not require any special storage conditions


Nature and contents of container

Opaque, white PVC with PVdC (polyvinylidene chloride), heat-sealed to aluminium foil,
blister pack containing:
4, 6, 8, 10, 12, 16, 20, 24, 32 film-coated tablets
Not all pack sizes may be marketed.


Special precautions for disposal

No special requirements.



Reckitt Benckiser Healthcare (UK) Ltd
Slough, SL1 3UH



PL 00063/0649






Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.